AtaiBeckley Inc. Common Stock (ATAI)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with the numbers, and AtaiBeckley does not look like a conventional bargain. The company is a clinical-stage biopharmaceutical firm with 99 employees, focused on mental-health therapies. In fiscal Q2 2026, revenue was $1.7 million and net income was -$32.5 million. Trailing free cash flow was -$132.6 million, a -7.6% free cash flow yield on a $1.7 billion market cap. That is heavy cash consumption for a business with very little current revenue. Graham would want tangible earnings and a margin of safety. Here, EPS is -$2.79, P/E is -2.63, and price-to-book is 15.31 at the 2026-09-11 close of $7.35. ROE is -417.21% and ROCE is -39.03%. The Piotroski score is 2/9, confirming weak fundamental momentum. The one balance-sheet positive is low leverage: debt-to-equity is 0.02, and Altman Z-score 4.76 suggests low bankruptcy risk on these inputs, though that metric is not designed for clinical-stage biotech. The stock is near the top of its 52-week range of $3.27 to $7.45, with beta 1.55. FairStock score 32/100. There is no Lynch category because only zero years of filed results are available; the company lacks the multi-year record I prefer. The pipeline, BPL-003 and ELE-101, may hold option value, but that is speculation, not demonstrated earning power. Without evidence of a durable moat, positive cash flow, or a clear margin of safety, I see the price as built on clinical hope rather than proven business value.

In plain English: AtaiBeckley is a small healthcare company trying to develop new treatments for mental health conditions. It is not yet making steady profits: in the latest quarter it had $1.7 million of revenue and lost $32.5 million, and it burned cash. Based only on the numbers, the business looks weak today and the stock price looks expensive relative to those results, though investors may be paying for future drug possibilities.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-09-11 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer